Cervical cancer control, priorities and new directions

Joseph Monsonego, F. Xavier Bosch, Pierre Coursaget, John Thomas Cox, Eduardo Franco, Ian Frazer, Rengaswamy Sankaranarayanan, John Schiller, Albert Singer, Tom Wright, Walter Kinney, Chris Meijer, James Linder

Research output: Contribution to journalShort survey

98 Citations (Scopus)

Abstract

Cervical cancer is caused by infection with a range of high risk "oncogenic" human papillomavirus (HPV) types, and it is now accepted that >99% of cervical cancer is initiated by HPV infection. The estimated lifetime risk of cervical cancer is nevertheless relatively low (less than 1 in 20 for most community based studies). Although sensitivity and specificity of the available diagnostic techniques are suboptimal, screening for persistent HPV infection is effective in reducing the incidence of cervical cancer. Infection can be detected by molecular techniques or by cytological examination of exfoliated cervical cells. Persistent infection is the single best predictor of risk of cervical cancer. The latest findings of HPV and cervical cancer research need to be widely disseminated to the scientific and medical societies that are updating screening and management protocols, public health professionals, and to women and clinicians. This report reviews current evidence, clinical implications and directions for further research in the prevention, control and management of cervical cancer. We report the conclusions of the Experts' Meeting at the EUROGIN 2003 conference.

Original languageEnglish (US)
Pages (from-to)329-333
Number of pages5
JournalInternational Journal of Cancer
Volume108
Issue number3
DOIs
StatePublished - Jan 20 2004

Fingerprint

Uterine Cervical Neoplasms
Papillomavirus Infections
Cytological Techniques
Infection
Medical Societies
Direction compound
Research
Public Health
Sensitivity and Specificity
Incidence

Keywords

  • Cervical neoplasia
  • Colposcopy
  • HPV vaccine
  • Human papillomavirus
  • Screening

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Monsonego, J., Bosch, F. X., Coursaget, P., Cox, J. T., Franco, E., Frazer, I., ... Linder, J. (2004). Cervical cancer control, priorities and new directions. International Journal of Cancer, 108(3), 329-333. https://doi.org/10.1002/ijc.11530

Cervical cancer control, priorities and new directions. / Monsonego, Joseph; Bosch, F. Xavier; Coursaget, Pierre; Cox, John Thomas; Franco, Eduardo; Frazer, Ian; Sankaranarayanan, Rengaswamy; Schiller, John; Singer, Albert; Wright, Tom; Kinney, Walter; Meijer, Chris; Linder, James.

In: International Journal of Cancer, Vol. 108, No. 3, 20.01.2004, p. 329-333.

Research output: Contribution to journalShort survey

Monsonego, J, Bosch, FX, Coursaget, P, Cox, JT, Franco, E, Frazer, I, Sankaranarayanan, R, Schiller, J, Singer, A, Wright, T, Kinney, W, Meijer, C & Linder, J 2004, 'Cervical cancer control, priorities and new directions', International Journal of Cancer, vol. 108, no. 3, pp. 329-333. https://doi.org/10.1002/ijc.11530
Monsonego J, Bosch FX, Coursaget P, Cox JT, Franco E, Frazer I et al. Cervical cancer control, priorities and new directions. International Journal of Cancer. 2004 Jan 20;108(3):329-333. https://doi.org/10.1002/ijc.11530
Monsonego, Joseph ; Bosch, F. Xavier ; Coursaget, Pierre ; Cox, John Thomas ; Franco, Eduardo ; Frazer, Ian ; Sankaranarayanan, Rengaswamy ; Schiller, John ; Singer, Albert ; Wright, Tom ; Kinney, Walter ; Meijer, Chris ; Linder, James. / Cervical cancer control, priorities and new directions. In: International Journal of Cancer. 2004 ; Vol. 108, No. 3. pp. 329-333.
@article{b1684cc352a842c794775e62eca66518,
title = "Cervical cancer control, priorities and new directions",
abstract = "Cervical cancer is caused by infection with a range of high risk {"}oncogenic{"} human papillomavirus (HPV) types, and it is now accepted that >99{\%} of cervical cancer is initiated by HPV infection. The estimated lifetime risk of cervical cancer is nevertheless relatively low (less than 1 in 20 for most community based studies). Although sensitivity and specificity of the available diagnostic techniques are suboptimal, screening for persistent HPV infection is effective in reducing the incidence of cervical cancer. Infection can be detected by molecular techniques or by cytological examination of exfoliated cervical cells. Persistent infection is the single best predictor of risk of cervical cancer. The latest findings of HPV and cervical cancer research need to be widely disseminated to the scientific and medical societies that are updating screening and management protocols, public health professionals, and to women and clinicians. This report reviews current evidence, clinical implications and directions for further research in the prevention, control and management of cervical cancer. We report the conclusions of the Experts' Meeting at the EUROGIN 2003 conference.",
keywords = "Cervical neoplasia, Colposcopy, HPV vaccine, Human papillomavirus, Screening",
author = "Joseph Monsonego and Bosch, {F. Xavier} and Pierre Coursaget and Cox, {John Thomas} and Eduardo Franco and Ian Frazer and Rengaswamy Sankaranarayanan and John Schiller and Albert Singer and Tom Wright and Walter Kinney and Chris Meijer and James Linder",
year = "2004",
month = "1",
day = "20",
doi = "10.1002/ijc.11530",
language = "English (US)",
volume = "108",
pages = "329--333",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Cervical cancer control, priorities and new directions

AU - Monsonego, Joseph

AU - Bosch, F. Xavier

AU - Coursaget, Pierre

AU - Cox, John Thomas

AU - Franco, Eduardo

AU - Frazer, Ian

AU - Sankaranarayanan, Rengaswamy

AU - Schiller, John

AU - Singer, Albert

AU - Wright, Tom

AU - Kinney, Walter

AU - Meijer, Chris

AU - Linder, James

PY - 2004/1/20

Y1 - 2004/1/20

N2 - Cervical cancer is caused by infection with a range of high risk "oncogenic" human papillomavirus (HPV) types, and it is now accepted that >99% of cervical cancer is initiated by HPV infection. The estimated lifetime risk of cervical cancer is nevertheless relatively low (less than 1 in 20 for most community based studies). Although sensitivity and specificity of the available diagnostic techniques are suboptimal, screening for persistent HPV infection is effective in reducing the incidence of cervical cancer. Infection can be detected by molecular techniques or by cytological examination of exfoliated cervical cells. Persistent infection is the single best predictor of risk of cervical cancer. The latest findings of HPV and cervical cancer research need to be widely disseminated to the scientific and medical societies that are updating screening and management protocols, public health professionals, and to women and clinicians. This report reviews current evidence, clinical implications and directions for further research in the prevention, control and management of cervical cancer. We report the conclusions of the Experts' Meeting at the EUROGIN 2003 conference.

AB - Cervical cancer is caused by infection with a range of high risk "oncogenic" human papillomavirus (HPV) types, and it is now accepted that >99% of cervical cancer is initiated by HPV infection. The estimated lifetime risk of cervical cancer is nevertheless relatively low (less than 1 in 20 for most community based studies). Although sensitivity and specificity of the available diagnostic techniques are suboptimal, screening for persistent HPV infection is effective in reducing the incidence of cervical cancer. Infection can be detected by molecular techniques or by cytological examination of exfoliated cervical cells. Persistent infection is the single best predictor of risk of cervical cancer. The latest findings of HPV and cervical cancer research need to be widely disseminated to the scientific and medical societies that are updating screening and management protocols, public health professionals, and to women and clinicians. This report reviews current evidence, clinical implications and directions for further research in the prevention, control and management of cervical cancer. We report the conclusions of the Experts' Meeting at the EUROGIN 2003 conference.

KW - Cervical neoplasia

KW - Colposcopy

KW - HPV vaccine

KW - Human papillomavirus

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=10744223758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744223758&partnerID=8YFLogxK

U2 - 10.1002/ijc.11530

DO - 10.1002/ijc.11530

M3 - Short survey

C2 - 14648697

AN - SCOPUS:10744223758

VL - 108

SP - 329

EP - 333

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -